Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Global X Genomics & Biotechnology UCITS ETF
a sub-fund of **Global X ETFs ICAV**
USD Accumulating Share Class (IE00BM8R0N95)

Manufacturer: Global X Management Company (Europe) Limited, part of the Global X group of companies.

The Central Bank of Ireland is responsible for supervising Global X Management Company (Europe) Limited in relation to this Key Information Document.
This PRIIP is authorised in Ireland.
Global X Management Company (Europe) Limited is authorised in Ireland and regulated by the Central Bank of Ireland.
For more information on this product, please visit www.globalxetfs.eu, email europe@globalxetfs.com or call : +44 (0)20 4529 2551.

This document was produced on 21 August 2025.

What is this product?

Type:
This product is a UCITS fund.
Term:
This is an Open Ended Fund.
Objectives:
The Fund's investment objective is to generate returns that closely correspond, before fees and expenses, generally to the price and yield performance of the Solactive Genomics v2 Index (the **"Index"**).
The Fund is passively managed. The Fund will aim to achieve its investment objective by attempting to replicate the performance of the Index by investing primarily in a portfolio of equity securities that as far as possible and practicable consists of the component securities of the Index in similar proportions to their weightings in the Index and in american depositary receipts (**"ADRs"**) and global depositary receipts (**"GDRs"**) based on the securities in the Index.
The Index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, **"Genomics & Biotechnology Companies"**), as defined by Solactive AG (the **"Index Provider"**).
Genomic and Biotechnology Companies include those involved in the following business activities (i) genomic editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics.
In order to be eligible for inclusion in the Index, a company shall generate revenues from relevant activities. (i) Pure-Play which derives at least 50% of revenues from genomics activities which means a process that involves exploring and understanding the structure, function, and evolution of genomes ("Genomics Activities"). (ii) Pre-Revenue which has primary business operations in Genomics Activities but does not currently generate revenues. (iii) Diversified which derives revenues from Genomics Activities but less than 50%.
When not possible or practicable to continue to hold all of the component securities of the Index, the Fund may invest in depositary receipts relating either to components securities of the Index or to equity securities of the type referred to above; and financial derivative instruments (**"FDIs"**), namely, total return "unfunded" OTC swaps and exchange-traded equity futures for investment purposes.
The Fund may enter into securities lending transactions, investing in repurchase and reverse repurchase transactions and collective investment schemes, for the purposes of efficient portfolio management only.
The Fund's base currency is USD.
For Accumulating Shares, income will be automatically reinvested in the Fund and reflected in the NAV per share.
Investors can buy and sell shares of the Fund on each business day. Business day means a day on which the New York Stock Exchange and London Stock Exchange are open for normal business.
For more information about the investment policy and strategy of the Fund, please refer to the sections entitled "Investment Objective" and "Investment Policy" in the Fund's supplement. Fund documents including the Prospectus, Supplement and the latest annual and half-yearly reports are available free of charge in English. These can be found, along with other information, such as share prices and classes, on the Fund's website at www.globalxetfs.eu.
The depositary is SEI Investments - Depositary and Custodial Services (Ireland) Limited.
This document describes a sub-fund of the UCITS. The Prospectus and periodic reports are prepared in respect of the entire UCITS. The assets and liabilities of each sub-fund of the UCITS are segregated by law, and so the assets of one sub-fund cannot be used to discharge the liabilities of another sub-fund.
Intended retail investor:
This Fund is intended for investors who want to take a long or short-term exposure to the market covered by the index of the Fund and would be prepared to take on a medium level of risk associated with an investment of this type, including potential volatility of such market. Such an investor must also be one that is able to assess the merits and risks of an investment in the Shares of the relevant Class of the Fund.

What are the risks and what could I get in return?

Risk Indicator



The risk indicator assumes you keep the product for 5 years.
The actual risk can vary significantly if you cash in at an early stage and you may get back less.
The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.
We have classified this product as 6 out of 7, which is the second-highest risk class. This rates the potential losses from future performance at a high level, and poor market conditions are very likely to impact the ability for you to receive a positive return on your investment.
Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.
This product does not include any protection from future market performance so you could lose some or all of your investment. If we are not able to pay you what is owed, you could lose your entire investment.
For other risks materially relevant to the product which are not taken into account in the summary risk indicator, please read the Prospectus and Supplement available at www.globalxetfs.eu.

Performance scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor / and includes the costs of your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of Global X Genomics & Biotechnology UCITS ETF over the last 10 years.

The stress scenario shows what you might get back in extreme market circumstances. Markets could develop very differently in the future.

What you will get from this product depends on future market performance. Market developments in the future cannot be accurately predicted. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower.

Recommended Holding Period: 5 years

Investment: USD 10,000

Scenarios Minimum: There is no minimum guaranteed return if you exit before 5 years		If you exit after 1 year	If you exit after 5 years (recommended holding period)
Stress	**What you might get back after costs** Average return each year	2,160 USD -78.44%	880 USD -38.50%
Unfavourable[1]	**What you might get back after costs** Average return each year	6,060 USD -39.36%	3,600 USD -18.48%
Moderate[2]	**What you might get back after costs** Average return each year	10,750 USD 7.50%	13,840 USD 6.72%
Favourable[3]	**What you might get back after costs** Average return each year	17,200 USD 72.04%	29,950 USD 24.53%

[1] This type of scenario occurred for an investment between October 2021 and May 2025.
[2] This type of scenario occurred for an investment between September 2017 and September 2022.
[3] This type of scenario occurred for an investment between June 2016 and June 2021.

What happens if Global X Management Company (Europe) Limited, part of the Global X group of companies is unable to pay out?

You may face a financial loss should the manufacturer or depositary/custodian, SEI Investments – Depositary and Custodial Services (Ireland) Limited, default on their obligations.

There is no compensation or guarantee scheme in place which may offset, all or any of, this loss.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed, in the first year you would get back the amount that you invested (0 % annual return). For the other holding period, we have assumed the fund performs as shown in the moderate scenario and the investment is USD 10,000.

Investment: USD 10,000	If you exit after 1 year	If you exit after 5 years
Total costs	54 USD	358 USD
Annual cost impact (*)	0.5%	0.6%

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 7.3% before costs and 6.7% after costs.

Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	None * * Secondary market investors (Investors dealing on a stock exchange) may pay fees charged by their stockbrokers. Such charges, if any, can be obtained from stockbrokers. Authorised participants dealing directly with the Fund will pay related transaction costs related to their subscriptions and redemptions.	0 USD
Exit costs	None * * Secondary market investors (Investors dealing on a stock exchange) may pay fees charged by their stockbrokers. Such charges, if any, can be obtained from stockbrokers. Authorised participants dealing directly with the Fund will pay related transaction costs related to their subscriptions and redemptions.	0 USD
Ongoing costs taken each year		**If you exit after 1 year**
Management fees and other administrative or operating costs	0.5% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell. The annual management fee for this product is 0.5%.	50 USD
Transaction costs	0.0% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	4 USD
Incidental costs taken under specific conditions		**If you exit after 1 year**
Performance fees	This product does not have any performance fees.	0 USD

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

This product has no required minimum holding period but is designed for long term investment; you should be prepared to stay invested for at least 5 years. The 5 years has been calculated to be in line with the time frame which the Product may need in order to achieve its investment objectives. You may sell your shares in the product, without penalty, on any day on which the banks are normally open for business in Ireland and on which the New York Stock Exchange and London Stock Exchange are open for normal business.

The value of your investments may go down as well as up irrespective of the period you are holding your investments, depending on such factors as the performance of the Fund, movements in stock and bond prices, and conditions in financial markets generally. Please contact your broker, financial adviser or distributor for information on any costs and charges relating to the sale of the shares.

How can I complain?

If you have any complaints about the product, the conduct of the manufacturer or the person advising on the product, complaints can be lodged free of charge via the following methods:

i. Phone: +44 (0)20 4529 2551

ii. E-mail: complaints@globalxetfs.com

iii. Mail: 10 Earlsfort Terrace, Dublin 2, Ireland

iv. Online: www.globalxetfs.eu/

You also have the right to refer the relevant complaint to the Financial Services and Pensions Ombudsman after following the Fund's complaints process if you are still not satisfied with the response received. Further information on the complaints policy relating to the Fund is available from www.globalxetfs.eu.

Other relevant information

We are required to provide you with further documentation, such as the product's latest prospectus, past performance annual and semi-annual reports. These documents and other product information are available online at https://globalxetfs.eu/priips-performance/.

To view the fund's historical performance and previous scenarios, please visit: www.globalxetfs.eu. Data on past performance is available for up to a maximum of 10 years.

The state of the origin of the fund is Ireland. In Switzerland, the representative is 1741 Fund Solutions AG, Burggraben 16, CH-9000 St.Gallen. The paying agent is Tellco Bank AG, Bahnhofstrasse 4, 6430 Schwyz. The prospectus, the KIDs or PRIIP-KIDs, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative.